Related Experiment Video
Updated: May 28, 2026
Assessment of Open Probability of the Mitochondrial Permeability Transition Pore in the Setting of Coenzyme Q Excess
Published on: June 1, 2022
Effects of Coenzyme Q10 on Lipid, Glycemic, and Inflammatory Markers in Metabolic Disorders: A Systematic Review and
Zhuo Zhang1, Zhuo Liu1, Yuli Geng1
1Institute of Integrated Traditional Chinese and Western Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China, hust.edu.cn.
Background:
The rising prevalence of metabolic disorders characterized by dyslipidemia and impaired glucose metabolism has increased interest in effective nutritional supplements. This systematic review and meta-analysis was conducted to evaluate the effects of coenzyme Q10 (CoQ10) on lipid profile, glycemic control, and inflammatory markers.
Methods:
PubMed, Web of Science, Scopus, Embase, Cochrane Library, and ClinicalTrials.gov were searched for eligible randomized controlled trials (RCTs). Random-effects models were applied to pool weighted mean differences (WMDs) or standardized mean differences (SMDs) with 95% confidence intervals (CIs).
Results:
A total of 64 RCTs (3422 participants) were included. Lipid profile: CoQ10 supplementation significantly improved blood triglyceride (TG, WMD = -5.67 mg/dL; 95% CI: -10.57, -0.77; p = 0.023), total cholesterol (TC, WMD = -4.86 mg/dL; 95% CI: -8.41, -1.30; p = 0.007), high-density lipoprotein cholesterol (HDL-C, WMD = 1.07 mg/dL; 95% CI: 0.22, 1.92; p = 0.013), and low-density lipoprotein cholesterol (LDL-C, WMD = -3.98 mg/dL; 95% CI: -7.00, -0.97; p = 0.010). Glycemic control: CoQ10 significantly reduced hemoglobin A1C (HbA1c, WMD = -0.22%; 95% CI: -0.37, -0.06; p = 0.006), fasting glucose (WMD = -10.07 mg/dL; 95% CI: -14.75, -5.39; p < 0.001), fasting insulin (FINS, WMD = -2.94 μIU/mL; 95% CI: -4.63, -1.25; p = 0.001), and homeostasis model assessment-insulin resistance (HOMA-IR, WMD = -0.82; 95% CI: -1.36, -0.28; p = 0.003). Inflammatory markers: CoQ10 significantly decreased C-reactive protein (CRP, WMD = -0.44 mg/L; 95% CI: -0.79, -0.09; p = 0.013), tumor necrosis factor-α (TNF-α, SMD = -1.01; 95% CI: -1.56, -0.64; p = 0.013), and interleukin-6 (IL-6, SMD = -0.42; 95% CI: -0.79, -0.05; p = 0.027) levels.
Conclusions:
CoQ10 supplementation has beneficial effects on lipid metabolism, glycemic control, and inflammation among individuals with metabolic disorders.
Related Concept Videos
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
01:24Overview of Lipid Metabolism
Lipolysis: The Breakdown of Lipids:
Lipolysis is the process of breaking down lipids, particularly triglycerides, into glycerol and fatty acids. This process typically occurs in the adipose tissue and is triggered by various hormones, including glucagon and...
01:17Ischemic Heart Disease: Overview
Atherosclerosis, the primary malefactor, orchestrates this dangerous condition. It manifests as the accumulation of fatty deposits, akin to insidious plaques, within arterial walls. As time elapses, these plaques metamorphose, hardening and narrowing...
01:15Diabetes: Management and Pharmacotherapy
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
01:22Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
01:24Type II Diabetes II: Pathophysiology